LATTICE vs Standard Radiotherapy for Cancer

Overseen By Camellia Djebroun

Age: Any Age

Sex: Any

Trial Phase: Phase 2

Sponsor: Stanford University

Disqualifiers: Prior radiation, Active pregnancy, Lupus, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two types of radiotherapy to determine which is more effective for treating metastatic cancer (cancer that has spread to other parts of the body). One group will receive LATTICE radiotherapy, which delivers a precise, powerful dose to the cancer, while the other group will receive standard radiotherapy. Individuals diagnosed with metastatic cancer and having one or two tumors larger than 2.5 cm, excluding those in the brain, may qualify to participate. The trial aims to identify which treatment better manages symptoms and improves quality of life. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Studies have shown that LATTICE radiotherapy is generally safe for treating cancer. Research indicates that patients tolerate this treatment well, with only 3.37% experiencing moderate-to-severe side effects. Most side effects are mild, occurring in about 19.40% of patients. Additionally, some studies reported no serious harmful effects, indicating the treatment is usually safe for most people.

Participants in these studies also reported benefits such as pain relief and improved movement. This suggests that LATTICE radiotherapy can enhance patient comfort while maintaining safety. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Researchers are excited about LATTICE Radiotherapy because it offers a new way to deliver radiation therapy that could potentially enhance effectiveness against cancer. Unlike standard radiotherapy, which delivers a uniform dose, LATTICE Radiotherapy uses a simultaneous integrated boost (SIB) technique to concentrate higher doses directly at the tumor site while sparing surrounding healthy tissue. This targeted approach not only aims to increase the treatment's potency but also potentially reduces side effects, making it a promising advancement over traditional methods.

What evidence suggests that this trial's treatments could be effective for cancer?

This trial will compare LATTICE Radiotherapy (LRT) with Standard Radiotherapy for cancer treatment. Studies have shown that LATTICE Radiotherapy effectively treats large tumors, particularly those exceeding 5 cm. Research indicates that this treatment can significantly shrink tumors, with some cases showing up to a 50% reduction within a few months. Patients have reported less pain and improved movement after receiving LRT. Specifically, one study found that about 79% of patients remained alive six months after treatment. LRT employs a special radiation pattern that targets the tumor while protecting healthy tissue, enhancing both its effectiveness and safety. ^{1 3 4 6 7}

Who Is on the Research Team?

Michael Gensheimer, MD

Principal Investigator

Stanford University

Are You a Good Fit for This Trial?

This trial is for people age 12 and older with confirmed metastatic cancer (tumors larger than 2.5 cm, not in the brain), who are well enough to do most daily activities. Both adults and teens can join if they or their guardians give consent, and women of childbearing age must have a negative pregnancy test.

Inclusion Criteria

I am 12 years old or older.

I am able to care for myself and perform daily activities.

My Lansky Play-Performance score is 50 or higher.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Radiotherapy

Participants receive either 5-fraction LATTICE radiotherapy or moderately dose-escalated palliative radiation

5 fractions

Follow-up

Participants are monitored for safety and effectiveness after treatment

90 +/- 20 days

What Are the Treatments Tested in This Trial?

Interventions

• LATTICE Radiotherapy
• Standard radiotherapy

Trial Overview

The study compares two types of palliative radiation: LATTICE radiotherapy (a newer method delivering higher doses to certain tumor areas) versus standard moderately increased-dose radiation. Patients are randomly assigned to one group or the other.

How Is the Trial Designed?

Group I: LATTICE Radiotherapy Experimental Treatment 1 Intervention

Participants receive 5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

Group II: Standard Radiotherapy Active Control 1 Intervention

Participants receive standard radiotherapy (25 Gy in 5 fractions)

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12240221/

Effectiveness and Safety of Lattice Radiotherapy in Treating ...

LRT exhibits encouraging efficiency and safety in patients with large solid tumors exceeding 5 cm in diameter.

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9406022/

Impressive Results after “Metabolism-Guided” Lattice ... - PMC

The lattice technique is a particular form of spatially fractionated radiation therapy, which was demonstrated to be safe and effective for treating advanced ...

3.

advancesradonc.org

advancesradonc.org/article/S2452-1094(24)00129-5/fulltext

Time-Related Outcome Following Palliative Spatially ...

Short-course LRT emerged as an effective and well-tolerated palliative option for very large lesions, whether treatment-naïve or previously irradiated. Nearly ...

4.

sciencedirect.com

sciencedirect.com/science/article/pii/S2666621925000237

Effectiveness and safety of 3D lattice radiation therapy in ...

The patient reported substantial pain relief and improved mobility post-treatment, with a follow-up MRI at three months showing a 22.5 % reduction in tumor size ...

5.

mdpi.com

mdpi.com/2072-6694/17/17/2752

Diagnosis-Related Outcome Following Palliative Spatially ...

Our formerly published clinical outcome data demonstrated the effectiveness and favorable safety of LRT in a heterogeneous cohort of 45 patients with 56 large ( ...

6.

link.springer.com

link.springer.com/article/10.1007/s12094-026-04260-5

Feasibility, safety, and clinical outcomes analysis of dense ...

Feasibility, safety, and clinical outcomes analysis of dense-lattice radiation therapy in palliative care for cancer patients´. RESEARCH ...

7.

springermedicine.com

springermedicine.com/radiotherapy/systemic-therapy/feasibility-safety-and-clinical-outcomes-analysis-of-dense-latti/52075674

Feasibility, safety, and clinical outcomes analysis of dense- ...

Results. The dense-LRT protocol was feasible and safe with no grade 3 acute or late toxicity reported. The 3 month CR and PR response rates were ...